Announcement • Jan 05

+ 3 more updates

Arcadium Lithium plc (NYSE:ALTM) completed the acquisition of Allkem Limited (ASX : AKE) in a merger of equals transaction.

Livent Corporation (NYSE:LTHM) signed a definitive agreement to acquire Allkem Limited (ASX:AKE) in a merger of equals transaction for $6.4 billion on May 10, 2023. The transaction would create the combine company value of $10.6 billion. NewCo will have a primary listing on the NYSE and maintain a foreign exempt listing on the ASX (via the issue of CDIs to Allkem shareholders). Under the terms of the Transaction, existing Allkem shareholders will receive one NewCo ASX listed CDI (or be able to elect to receive one NewCo NYSE listed share instead of a CDI) for each Allkem ordinary share held, except for shareholders in certain ineligible jurisdictions, who will receive cash proceeds from the sale of the NewCo CDIs in lieu of such CDIs after closing. Under the Merger, Livent shareholders will receive 2.406 NewCo NYSE listed shares of common stock for each Livent share held. Following the Transaction, Allkem and Livent shareholders are expected to own approximately 56% and 44% of the combined company, respectively. NewCo is to be incorporated in the Bailiwick of Jersey, with corporate headquarters to be in North America, with the exact location and company name to be announced at a later date, and corporate residency to be in Ireland. Upon completion of the Transaction, Peter Coleman will become the Chairman of NewCo, Paul Graves will become the Chief Executive Officer of NewCo, and Gilberto Antoniazzi will become the Chief Financial Officer of NewCo. The NewCo Board will have 14 members, consisting of 7 directors designated by Allkem and 7 directors designated by Livent. The commercial, operational, and capital deployment teams will be comprised of representatives from both companies. Allkem Chief Executive Officer, Martín Pérez de Solay, will provide consulting services to NewCo to help facilitate a smooth integration process post transaction close. As of August 2, 2023, each of Allkem's and Livent's Board of Directors have selected their respective nominees to the Board of NewCo which consists of six Livent nominees from Livent's current Board of Directors and six Allkem nominees from Allkem's current Board of Directors: Michael F. Barry; Peter Coleman (Chair designate of NewCo); Alan Fitzpatrick; Paul W. Graves (Chief Executive Officer designate of NewCo); Florencia Heredia; Leanne Heywood; Christina Lampe-Önnerud; Pablo Marcet; Steven T. Merkt; Robert C. Pallash; Fernando Oris de Roa; and John Turner. Richard Seville and Martin Perez de Solay (MD and CEO) from Allkem's Board of Directors, and Pierre R. Brondeau, Andrea E. Utecht and G. Peter D'Aloia from Livent's Board of Directors, will retire as directors upon closing of the transaction. In case of termination, either party will pay a termination fee of $64.6 million. Livent Corporation will be the accounting acquirer in the transaction. The transaction is expected to close by the end of calendar year 2023. Share for share exchange transaction expected to be a tax-free transaction for shareholders. The transaction have been unanimously approved by the Board of Directors of each company, and in the case of Allkem, subject to the Independent Expert concluding, and continuing to conclude, that the Scheme is in the best interest of Allkem shareholders. Closing of the Transaction is subject to the satisfaction or waiver of customary closing conditions, including receipt of regulatory approvals, approval by both Livent and Allkem shareholders, the Independent Expert concluding that the Scheme is in the best interest of Allkem shareholders and not changing, withdrawing, or qualifying that conclusion, tax opinion delivery, and Australian tax class ruling confirmation, and Australian Court approval. The Transaction Agreement includes reciprocal exclusivity arrangements (including notification obligations) in favour of both parties, a matching right regime in favour of both parties and termination fees in favour of both parties. The exclusivity arrangements are subject to customary exceptions that enable the directors of Allkem and Livent to comply with their respective fiduciary and/or statutory duties. As per filling on October 24, 2023, Livent and Allkem have agreed that the name of the combined company will be Arcadium Lithium plc. As of November 8, 2023, Federal Court of Australia approves convening of Scheme Meeting and dispatch of Scheme Booklet with merger effective date of January 4, 2024. As of November 14, 2023, all required pre-closing regulatory approvals in connection with the proposed merger have been received including antitrust approvals in Canada, China, Japan, South Korea and the U.S., as well as completion of investment screenings in Australia, the U.K. and the U.S. The closing of the Transaction remains subject to approval by both Livent and Allkem shareholders, and Australian Court approval of the Scheme. As on November 15, 2023, the proposed merger of Allkem and Livent Corporation has received Australian Foreign Investment Review Board approval. Allkem, Livent and NewCo have now received antitrust/competition approvals in Canada, China, Japan, South Korea and the U.S., as well as foreign investment approvals/completion of investment screenings in Australia, the U.K. and the U.S. This represents all competition and foreign investment approvals that are expected to be required prior to completion. As per filling on December 19, 2023, Allkem shareholders vote in favour of merger with Livent and a final court approval is still pending. If the Court approves the Scheme at the Second Court Hearing, Allkem intends to lodge a copy of the orders of the Court with the Australian Securities and Investments Commission on December 21, 2023. As of December 19, 2023, Livent and Allkem announced that they have obtained all requisite shareholder approvals necessary to complete the merger of equals. The two companies expect to close the merger on January 4, 2024 and begin operating under the name Arcadium Lithium plc (NYSE:ALTM) (ASX:LTM). Gordon Dyal & Co., LLC. is acting as exclusive financial advisor and William H. Aaronson, Cheryl Chan, William A. Curran, Kyoko Takahashi Lin, Michael Kaplan, Howard Shelanski and Suzanne Munck af Rosenschold of Davis Polk & Wardwell LLP and Guy Alexander, Dave Filov, Bryn Hardcastle, Andrew Wong, Ellen Thomas and Adrian Chek of Allens are acting as legal counsel to Livent. Gordon Dyal & Co. Advisory Group LP acted as fairness opinion provider to the board of directors of Livent. Livent has agreed to pay Gordon Dyal & Co. a fee of $35.0 million for Gordon Dyal & Co.’s services rendered in connection with the transaction. UBS Securities Australia Limited and Morgan Stanley & Co. LLC are acting as financial advisors and Antonella Pacitti, Roger Davies, Cairo Leicester and Tom Carmody of King & Wood Mallesons and Joseph P. Michaels, Brian J. Fahrney, James Wood, Rachel D. Kleinberg, Jason Menzies, Sonia Gupta Barros, Sara M. von Althann, William Blumenthal, Vincent Brophy, Rosanna Connolly, Laura Collins, Andrew Shoyer, James Mendenhall, Sven De Knop, Grigore Alexandru, Matthew E. Johnson, Christian E. Pilhofer, Teresa L. Reuter, Elizabeth K. McCloy, Heather M. Palmer, Anna Remis, Sarah A. Jehl and Tim Chandler of Sidley Austin LLP are acting as legal counsel to Allkem. Fasken Martineau DuMoulin LLP acted as a legal advisor to Allkem Limited. Morrow Sodali acted as a proxy solicitor to Livent Corporation. Simon Dinning and Alexander Curry of Ogier LLP acted as legal advisors for Livent. Arcadium Lithium plc (NYSE:ALTM) completed the acquisition of Allkem Limited (ASX : AKE) in a merger of equals transaction on January 4, 2024. Arcadium Lithium ordinary shares will begin trading today on the NYSE under the ticker "ALTM." Arcadium Lithium also maintains a foreign exempt listing on the ASX (via the issue of CHESS Depositary Instruments (CDIs) to Allkem shareholders) and will commence trading on a normal settlement basis on the ASX under the ticker "LTM" on January 5, 2024.

Total Shareholder Yield	0.4%
Future Dividend Yield	1.3%
Dividend Growth	n/a
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Payout ratio	n/a

Segment	Dividend Yield
Company (AKE)	n/a
Market Bottom 25% (AU)	2.7%
Market Top 25% (AU)	6.7%
Industry Average (Metals and Mining)	3.4%
Analyst forecast (AKE) (up to 3 years)	1.3%

Data	Last Updated (UTC time)
Company Analysis	2024/01/06 01:41
End of Day Share Price	2023/12/21 00:00
Earnings	2023/06/30
Annual Earnings	2023/06/30

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

Analyst	Institution
Joel Jackson	BMO Capital Markets Equity Research
James Redfern	BofA Global Research
Reg Spencer	Canaccord Genuity

This company listing is no longer active

Allkem Dividends and Buybacks

Dividend criteria checks 0/6

Key information

Recent dividend and buyback updates

Recent updates

Allkem Limited Ordinary Shares to Be Deleted from OTC Equity

Arcadium Lithium plc (NYSE:ALTM) completed the acquisition of Allkem Limited (ASX : AKE) in a merger of equals transaction.

Allkem Limited(ASX:AKE) dropped from S&P Global BMI Index

Investor sentiment improves as stock rises 15%

Here's Why Allkem (ASX:AKE) Can Manage Its Debt Responsibly

Consensus revenue estimates fall by 10%

Is Allkem Limited (ASX:AKE) Trading At A 24% Discount?

Now 20% undervalued after recent price drop

Here's Why We Think Allkem (ASX:AKE) Is Well Worth Watching

Allkem Limited Announces A Project Update to Its Wholly Owned Cauchari Lithium Brine Project Located in Jujuy Province in Argentina

Allkem Limited Announces Update to Olaroz Lithium Brine Operation Located in Jujuy Province in Argentina

Does Allkem (ASX:AKE) Have A Healthy Balance Sheet?

Consensus EPS estimates fall by 10%

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Allkem Limited Provides an Updated Mineral Resource Estimate for Its James Bay Lithium Project in Québec, Canada

Allkem Limited Provides Drilling Update for James Bay Lithium Project in Qubec, Canada

Allkem Limited Provides an Ore Reserve Update for Its Mt Cattlin Operation in Western Australia

Allkem Limited's (ASX:AKE) Intrinsic Value Is Potentially 50% Above Its Share Price

Allkem Limited Reports 34% Increase to Mt Cattlin Mineral Reserve

Allkem Limited (ASX:AKE) signed a definitive agreement to acquire Livent Corporation (NYSE:LTHM) in a merger of equals transaction for $3.7 billion.

Investor sentiment improves as stock rises 25%

Allkem Limited Provides an Update on the Exploration and Resource Definition Drilling Program At Its James Bay Project in Qubec, Canada

Investor sentiment improves as stock rises 20%

Allkem (ASX:AKE) Has A Pretty Healthy Balance Sheet

Independent Non-Executive Director recently bought AU$213k worth of stock

Investor sentiment deteriorates as stock falls 17%

Chair recently bought AU$198k worth of stock

First half 2023 earnings released

Allkem Limited Announces Chief Financial Officer Changes

Allkem Limited to Report First Half, 2023 Results on Feb 24, 2023

Allkem Limited (ASX:AKE) acquired María Victoria Lithium Tenement from Minera Santa Rita S.R.L.

Minera Santa Rita S.R.L. completed the acquisition of Borax Argentina S.A. from Allkem Limited (ASX:AKE).

Allkem Limited to Report Q1, 2024 Results on Oct 26, 2023

These 4 Measures Indicate That Allkem (ASX:AKE) Is Using Debt Reasonably Well

Key Executive recently bought AU$251k worth of stock

Allkem Limited Announces Retirement of Mr. Martin Rowley as Chair and Director

High number of new directors

Allkem Limited and Toyota Tsusho Corporation Produces First Lithium Hydroxide at Naraha

High number of new directors

Allkem Limited Provides an Update on the Resource Extension Drilling Program Currently Underway At Its Mt Cattlin Spodumene Operation in Western Australia

Allkem Limited Announces Retirement of Deputy Chair, Rob Hubbard

Allkem Limited Announces Board Changes

Consensus EPS estimates increase by 12%

Consensus EPS estimates increase by 10%

Investor sentiment improved over the past week

Non-Executive Director recently sold AU$21m worth of stock

Price target increased to AU$16.07

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Allkem Limited Revises Production Guidance for the Full Year 2023 and Provides Production Guidance for the Fiscal Year 2024

Minera Santa Rita S.R.L. entered into a binding and conditional Heads of Agreement to acquire Borax Argentina S.A. from Allkem Limited (ASX:AKE).

Allkem Limited to Report Fiscal Year 2022 Results on Aug 25, 2022

Allkem Limited Announces Executive Appointments

Allkem Limited Provides Production Guidance for the Full Year 2023

Allkem Limited to Report Q4, 2022 Results on Jul 20, 2022

Allkem Limited to Commence Three-Phase Resource Extension Drilling Program and Announces Resource Update

Allkem Limited Announces Management Appointments

Price target increased to AU$15.05

Allkem Limited Advises an Update to its Wholly Owned Sal de Vida Project Located in Catamarca Province in Argentina

Allkem Limited to Report Q3, 2022 Results on Apr 14, 2022

Is Allkem (ASX:AKE) Using Too Much Debt?

First half 2022 earnings: Revenues miss analyst expectations

Estimating The Fair Value Of Allkem Limited (ASX:AKE)

Allkem Limited to Report First Half, 2022 Results on Feb 28, 2022

Price target increased to AU$11.39

Does Allkem (ASX:AKE) Have A Healthy Balance Sheet?

Allkem Limited Advises the Release of the Feasibility Study and Maiden Ore Reserve for Its Wholly Owned James Bay Lithium Project

Here's Why Orocobre Limited's (ASX:ORE) CEO Compensation Is The Least Of Shareholders' Concerns

MD, CEO & Director recently sold AU$460k worth of stock

Non-Executive Director recently sold AU$7.8m worth of stock

Price target increased to AU$8.62

Full year 2021 earnings released: US$0.18 loss per share (vs US$0.20 loss in FY 2020)

Independent Non-Executive Director John Gibson has left the company

Non-Executive Director Masaharu Katayama has left the company

Director Patricia Martinez has left the company